This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Mar 1;5(3):433-434.

doi: 10.1001/jamaoncol.2018.6683.

Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test

Chiara Nicolazzo¹, Angela Gradilone¹, Paola Gazzaniga¹

Affiliations

PMID: 30703189
DOI: 10.1001/jamaoncol.2018.6683

Comment

Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test

Chiara Nicolazzo et al. JAMA Oncol. 2019.

. 2019 Mar 1;5(3):433-434.

doi: 10.1001/jamaoncol.2018.6683.

Authors

Chiara Nicolazzo¹, Angela Gradilone¹, Paola Gazzaniga¹

Affiliation

¹ Circulating Tumor Cells Unit, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

PMID: 30703189
DOI: 10.1001/jamaoncol.2018.6683

No abstract available

PubMed Disclaimer

Comment in

Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test-In Reply.
Bamford P, Dittamore R, Scher HI. Bamford P, et al. JAMA Oncol. 2019 Mar 1;5(3):434. doi: 10.1001/jamaoncol.2018.6686. JAMA Oncol. 2019. PMID: 30703186 No abstract available.

Comment on

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.
Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, McLaughlin B, Lu D, Fleisher M, Orr S, Lowes L, Anderson A, Wang Y, Dittamore R, Allan AL, Attard G, Heller G. Scher HI, et al. JAMA Oncol. 2018 Sep 1;4(9):1179-1186. doi: 10.1001/jamaoncol.2018.1621. JAMA Oncol. 2018. PMID: 29955787 Free PMC article.

Similar articles

Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test-In Reply.
Bamford P, Dittamore R, Scher HI. Bamford P, et al. JAMA Oncol. 2019 Mar 1;5(3):434. doi: 10.1001/jamaoncol.2018.6686. JAMA Oncol. 2019. PMID: 30703186 No abstract available.
Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail.
Plymate SR, Sharp A, de Bono JS. Plymate SR, et al. JAMA Oncol. 2018 Sep 1;4(9):1187-1188. doi: 10.1001/jamaoncol.2018.1615. JAMA Oncol. 2018. PMID: 29955776 No abstract available.
Clinical Acumen Versus Androgen Receptor Variant 7 Circulating Tumor Cells in Decision-Making for Men with Advanced Prostate Cancer.
Montgomery B, Plymate S. Montgomery B, et al. Eur Urol. 2020 Feb;77(2):178-179. doi: 10.1016/j.eururo.2019.09.028. Epub 2019 Oct 13. Eur Urol. 2020. PMID: 31615710 No abstract available.
Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
Bryce AH, Antonarakis ES. Bryce AH, et al. Int J Urol. 2016 Aug;23(8):646-53. doi: 10.1111/iju.13134. Epub 2016 Jun 3. Int J Urol. 2016. PMID: 27255944 Review.
Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H, Wang Z, Tang K, Zhou H, Liu H, Yan L, Guan W, Chen K, Xu H, Ye Z. Li H, et al. Eur Urol Focus. 2018 Jul;4(4):529-539. doi: 10.1016/j.euf.2017.01.004. Epub 2017 Jan 23. Eur Urol Focus. 2018. PMID: 28753843

See all similar articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems